{"schema_version":"secwatch.filing_event.v1","accession":"0001516551-25-000050","form_type":"8-K","ticker":"SKYE","cik":"0001516551","company_name":"Skye Bioscience, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.190182+00:00","generated_at":"2026-05-17T17:29:09.398769+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Skye Bioscience Q2 net loss $17.6M; Phase 2a top-line data due late Q3/early Q4 2025","bullets":["Net loss of $17.6M for Q2 2025, vs $7.9M in Q2 2024; R&D expense rose to $14.3M from $4.1M.","Cash, equivalents & short-term investments $48.6M as of June 30, 2025; expected to fund operations through at least Q1 2027.","Phase 2a CBeyond study of nimacimab top-line data expected late Q3/early Q4 2025; extension study enrolling.","Preclinical data: nimacimab + low-dose tirzepatide boosted weight loss beyond optimal tirzepatide; nimacimab reduced post-treatment weight rebound."],"urls":{"canonical":"https://secwatch.observer/filing/0001516551-25-000050","json":"https://secwatch.observer/filing/0001516551-25-000050.json","markdown":"https://secwatch.observer/filing/0001516551-25-000050.md","text":"https://secwatch.observer/filing/0001516551-25-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1516551/000151655125000050/0001516551-25-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1516551/000151655125000050/skye-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:29:09.398769+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}